Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
暂无分享，去创建一个
J. Blay | M. van Glabbeke | R. Sciot | J. Verweij | B. Bui | R. Issels | P. Schőffski | A. Le Cesne | S. Leyvraz | P. Casali | I. Judson | P. Reichardt | P. Hogendoorn | M. Findlay | M. V. Van Glabbeke